Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 6, 2006, Pages 931-939

  Briasoulis, Evangelos ^a   Liakakos, Theodore ^b   Dova, Lefkothea ^c   Fatouros, Michael ^d   Tsekeris, Pericles ^d   Roukos, Dimitrios H ^e   Kappas, Angelos M ^d  

^a Department of Medical Oncology ^*  (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adjuvant treatment; Biomarkers; Chemotherapy; Gastric cancer; Localized disease; Postoperative; Preoperative; Targeted therapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; TAXANE DERIVATIVE; TEGAFUR; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EARLY CANCER; EXPECTATION; GASTRECTOMY; GENE EXPRESSION PROFILING; HUMAN; INDIVIDUALIZATION; LUNG CANCER; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STOMACH CANCER; SURVIVAL RATE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; DECISION MAKING; METHODOLOGY; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE COMPLICATION; PROGNOSIS; STOMACH TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DECISION MAKING; GASTRECTOMY; HUMANS; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS;

EID: 33745126325     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.6.931     Document Type: Review

References (81)

1. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat. Clin. Pract. Oncol. 2(1), 98-107 (2005).
2. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29 (2004).
3. Fujii M, Sasaki J, Nakajima T. State of the art in the treatment of gastric cancer: from the 71st Japanese gastric cancer congress. Gastric Cancer 2, 151-157 (2003).
4. Sasako M. Principles of surgical treatment of curable gastric cancer. J. Clin. Oncol. 21, S274-S275 (1999).
5. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 5, 1-5 (2002).
6. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat. Rev. 26(4), 243-255 (2000).
7. In: AJCC Cancer Staging Manual (6th Edition). Greene FL, Page DL, Fleming ID (Eds). Springer-Verlag, New York, NY, USA (2002).
8. Lordick F, Stein HJ, Peschel C et al. Neoadjuvant therapy for oesophagogastric cancer. Br. J. Surg. 91, 540-551 (2004).
9. Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann. Surg. Oncol. 6(1), 46-56 (1999).
10. Jansen EP, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. J. Clin. Oncol. 23(20), 4509-4517 (2005).
11. Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann. Surg. Oncol. 11(2), 127-129 (2002).
12. Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J. Surg. Oncol. 81(2), 59-62 (2004).
13. Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann. Surg. Oncol. 7(4), 253-255 (2000).
14. Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann. Surg. Oncol. 9(9), 828-830 (2002).
15. Roukos DH, Kappas AM. Limitations in controlling risk of recurrence after curative surgery for advanced gastric cancer are now well-explained by molecular-based mechanisms. Ann. Surg. Oncol. 8, 620-621 (2001).
16. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys. 8, 1-11 (1982).
17. Wanebo HJ, Kennedy BJ, Chmiel J et al. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann. Surg. 218(5), 583-592 (1982).
18. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 88, 921-932 (2000).
19. Roukos DH, Lorenz M, Karakostas K et al. Pathological serosa and node-based classification accurately predicts gastric-cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients. Br. J. Cancer 84, 1602-1609 (2001).
20. Roukos D, Paraschou P. Adjuvant chemotherapy in gastric cancer. J. Clin. Oncol. 18(16), 3061-3062 (2000).
21. Allum WH, Griffin SM, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 50(Suppl. 5), S1-S23 (2002).
22. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 18(14), 2648-2657 (2000).
23. Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J. Clin. Oncol. 23(25), 6220-6232 (2005).
24. Imanaga H, Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J. Surg. 2(1), 213-221 (1977).
25. Maehara Y, Moriguchi S. Sakaguchi Y et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J. Surg. Oncol. 45(3), 169-172 (1990).
26. Lise M, Nitti D, Marchet A et al. Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Ann. Surg. Oncol. 2(6), 495-501 (1995).
27. Nitti D, Wils J, Dos Santos JG, Fountzilas G et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann. Oncol. 17(2), 262-269 (2006).
28. Bouche O, Ychou M, Burtin P et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann. Oncol. 16(9), 1488-1497 (2005).
29. Bajetta E, Buzzoni R, Mariani L et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann. Oncol. 13(2), 299-307 (2002).
30. Petrioli R, Sabatino M, Roviello F et al. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. Hepatogastroenterology 52(65), 1626-1630 (2005).
31. Carrato A, Gallego-Plazas J, Guillen-Ponce C. Adjuvant therapy of resected gastric cancer is necessary. Semin. Oncol. 32(6 Suppl. 9), S105-S108 (2005).
32. Leong T, Michael M, Foo K et al. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br. J. Cancer 89(8), 1433-1438 (2003).
33. Ross PJ, Hill ME, Norman A, Cunningham D. ECF in gastric cancer: J. Clin. Oncol. 18(22), 3874-3875 (2000).
34. Cunningham D, Allum WH, Stenning SP, Weeden S for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J. Clin. Oncol. (Meeting Abstracts) 23(16 Suppl.), 4001 (2005).
35. Kwon HC, Kim MC, Oh SY et al. Postoperative adjuvant 5-fluorouracil, cisplatin (FP) before and after chemoradiation with capecitabine versus FP alone in completely resected locally advanced gastric cancer. J. Clin. Oncol. (Meeting Abstracts) 23(16 Suppl.), 4146 (2005).
36. Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD. Ann. Oncol. 11(7), 837-843 (2000).
37. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur. J. Surg. 168(11), 597-608 (2002).
38. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer 35(7), 1059-1064 (1999).
39. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11(8), 1441-1447 (1993).
40. Panzini I, Gianni L, Fattori PP et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88(1), 21-27 (2002).
41. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725-730 (2001).
42. Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann. Surg. Oncol. 9(3), 620-621 (2002).
43. Falcone A. Future strategies and adjuvant treatment of gastric cancer: Ann. Oncol. (Suppl. 2), ii45-ii47 (2003).
44. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric cancer: Dutch Gastric Cancer Group. N. Engl. J. Med. 340(12), 908-914 (1999).
45. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer: 79(9-10), 1522-1530 (1999).
46. Nashimoto A, Nakajima T, Furukawa H et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J. Clin. Oncol. 21(12), 2282-2287 (2003).
47. Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur. J. Surg. Oncol. 30(3), 303-308 (2004).
48. Wu CW, Hsiung CA, Lo SS et al. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br. J. Surg. 91(3), 283-287 (2004).
49. Sano T, Sasako M, Yamamoto S et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group Study 9501. J. Clin. Oncol. 22(14), 2767-2773 (2004).
50. McCulloch P, Niita ME, Kazi H, Gama-Rodrigues JJ. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br. J. Surg. 92(1), 5-13 (2005).
51. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann. Surg. 228(4), 449-461 (1998).
52. Roukos DH, Kappas AM, Encke A. Extensive lymph-node dissection in gastric cancer: is it of therapeutic value? Cancer Treat. Rev. 22(4), 247-252 (1996).
53. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123(5), 573-578 (1998).
54. Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann. R. Coll. Surg. Engl. 80(1), 16-24 (1998).
55. Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 22, 2069-2077 (2004).
56. Fatouros M, Roukos DH, Lorenz M et al. Impact of spleen preservation in patients with gastric cancer: Anticancer Res. 25(4), 3023-3030 (2005).
57. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21(17), 3357-3365 (2003).
58. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N. Engl. J. Med. 350(4), 379-392 (2004).
59. Ott K, Sendler A, Becker K et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6(3), 159-167 (2003).
60. Zhang ZX, Gu XZ, Yin WB et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) - report on 370 patients. Int. J. Radiat. Oncol. Biol. Phys. 42(5), 929-934 (1998).
61. Ajani JA, Mansfield PF, Janjan N et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J. Clin. Oncol. 22, 2774-2780 (2004).
62. Yu W. Impact of perioperative intraperitoneal chemotherapy on the treatment of primary gastric cancer. Surg. Oncol. Clin. N. Am. 12(3), 623-634 (2003).
63. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 5(4), 219-228 (2004).
64. Xu DZ, Zhan YQ, Sun XW et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J. Gastroenterol. 10(18), 2727-2730 (2004).
65. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann. Surg. 240(5), 808-816 (2004).
66. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J. Clin. Oncol. 21(19), 3647-3650 (2003).
67. Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann. Surg. 243(1), 74-81 (2006).
68. Kappas AM, Fatouros M, Michos KM et al. Evidence-based approach: is it time to change funding, research policy and treatment strategy of gastric cancer in the western world? Gastric Breast Cancer 2(2), 24-27 (2003).
69. Gschwind A, Fischer OM, Ullrich A. The discovery of receptors tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4, 361-370 (2004).
70. Roukos et al. Can VEGF-D and VEGFR-3 be used as biomarkers for therapeutic decisions in patients with gastric cancer? Nat. Clin. Pract. Oncol. (2006) (In press).
71. Roukos DH, Agnantis NJ. Gene-expression profile: the future in the outcome prediction and treatment of breast cancer. Gastric Breast Cancer 2, 4-6 (2003).
72. Roukos DH, Paraskevaidis E, Kappas AM. Surgery in the era of gene expression profiling-based prediction and individualized, neoadjuvant breast cancer therapy: the beginning of the end? Ann. Surg. Oncol. 13(3), 433-435 (2006).
73. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 23(29), 7332-7341 (2005).
74. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 5(2), 142-149 (2005).
75. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845-856 (2005).
76. Juttner S, Wissmann C, Jons T et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J. Clin. Oncol. 24(2), 228-240 (2006).
77. Chen CN, Lin JJ, Chen JJ et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J. Clin. Oncol. 23(29), 7286-7295 (2005).
78. Gonzalez CA, Jakszyn P, Pera G et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J. Natl Cancer Inst. 98(5), 345-354 (2006).
79. Gonzalez CA, Pera G, Agudo A et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int. J. Cancer 118(10), 2559-2566 (2006).
80. Roukos DH, Paraskevaidis E, Agnantis NJ, Kappas AM. Fruits and vegetables: do they protect from gastric cancer? Gastroenterology 124(7), 2006-2007 (2003).
81. Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann. Surg. Oncol. 11(8), 727-730 (2004).